Related Experiment Video
Updated: Jun 20, 2026
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Immunotherapy of diffuse gliomas: biological background, current status and future developments
Oliver M Grauer1, Pieter Wesseling, Gosse J Adema
1Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Brain Pathology (Zurich, Switzerland)
|September 12, 2009
Summary
Diffuse gliomas are challenging to treat due to invasive cells. Immunotherapy offers a promising approach to target these resistant tumor cells, improving patient outcomes.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Research
Background:
- Diffuse gliomas exhibit invasive growth, evading conventional treatments like surgery, radiation, and chemotherapy.
- Current therapies for diffuse gliomas are often limited by significant local and systemic side effects.
- Novel therapeutic strategies are crucial for improving the prognosis of diffuse glioma patients.
Purpose of the Study:
- To review the immunological landscape of diffuse gliomas.
- To discuss the potential of immunotherapy for targeting glioma cells.
- To explore strategies for enhancing immunotherapy efficacy in glioma treatment.
Main Methods:
- Review of current literature on glioma immunology and immunotherapy.
- Analysis of immune responses within the central nervous system (CNS) in the context of gliomas.
- Discussion of various immunotherapy approaches targeting glioma-associated antigens.
Main Results:
- Significant advancements have been made in understanding CNS immune regulation and glioma-induced immunosuppression.
- Immunotherapy presents a targeted approach to eliminate residual tumor cells resistant to conventional therapies.
- Targeting glioma-associated antigens offers a strategy to spare healthy brain tissue.
Conclusions:
- Immunotherapy holds significant promise for treating diffuse gliomas by specifically targeting tumor cells.
- Further research into CNS immune mechanisms and immunotherapy strategies is essential for clinical translation.
- Optimizing immunotherapy efficacy is key to improving outcomes for patients with diffuse gliomas.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...